PIK3CA mutation – Medxy AI

Skip to content

Medxy AI

Wellness & Lifestyle
Clinical Updates
Medical News

Wellness & Lifestyle
Clinical Updates
Medical News

Search for:

facebook.com
twitter.com
t.me
instagram.com
youtube.com

Subscribe

Home
PIK3CA mutation

Posted inClinical Updates Wellness & Lifestyle

Inavolisib Improves Overall Survival in PIK3CA-Mutated Advanced Breast Cancer: Results from the INAVO120 Study

Posted by

By MedXY 08/01/2025

Inavolisib combined with palbociclib and fulvestrant significantly prolongs overall survival in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, but increases certain toxicities.

Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial
Ten-Year Outcomes of Partial-Breast Radiotherapy After Breast Conservation Surgery: Insights from the UK IMPORT LOW Trial
Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia
Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia
Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial

About us
Contact us
Privacy Policy
Subscribe Now!

English
日本語
Tiếng Việt
中文

aging Alzheimer's disease Antibiotics breast cancer clinical trial clinical trials diabetes diagnosis diet exercise FDA FDA approval GLP-1 health healthcare HIV Hypertension immunotherapy lifestyle lifestyle intervention longevity maternal health men's health Menopause mental health nutrition obesity older adults PCOS Pediatrics Physical Activity Pregnancy prevention public health randomized trial semaglutide sexual health sleep stroke treatment type 2 diabetes walking weight loss wellness women's health

Your health, we care

Scroll to Top